Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders

References

• Bleuler E. Dementia Praecox of the Group of Schizophrenias (1911). Zinkin J (Translator). International Universities Press, NY, USA (1950).
   Google Scholar
• Kraepelin E, Barclay R, Robertson GM. Dementia Praecox and Paraphrenia. E & S Livingstone, Edinburgh, UK (1919).
   Google Scholar
• Hughlings-Jackson J. Intellectual warnings of epileptic seizures. In: Selected Writings of John Hughlings-Jackson. Taylor J (Ed.). Hodder and Stoughton, London, UK, 274–275 (1931).
   Google Scholar
• Strauss J, Carpenter W. The prediction of outcome in schizophrenia: II. Relationships between predictors and outcome variables. Arch. Gen. Psychiatry31, 37–42 (1974).
   PubMed Web of Science ®Google Scholar
• Andreasen N, Olsen S. Negative v positive schizophrenia: definition and validation. Arch. Gen. Psychiatry39, 789–794 (1982).
   PubMed Web of Science ®Google Scholar
• Andreasen N, Grove W. Evaluation of positive and negative symptoms in schizophrenia. Psychiatry Psychobiol.1, 108–121 (1986).
   Google Scholar
• Schneider K. Clinical Psychopathology. Hamilton MW (Translator). Grune and Stratton Inc., NY, USA (1959).
   Google Scholar
• Carpenter WT, Strauss JS, Muleh S. Are there pathognomonic symptoms in schizophrenia: an empiric investigation of Schneider’s first-rank symptom. Arch. Gen. Psychiatry28, 847–852 (1973).
   PubMed Web of Science ®Google Scholar
• Liddle P. The symptoms of chronic schizophrenia: a re-examination of the positive–negative dichotomy. Br. J. Psychiatry151, 145–151 (1987).
   PubMed Web of Science ®Google Scholar
• Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr. Res.72, 29–39 (2004).
   PubMed Web of Science ®Google Scholar
• Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology23, 315–336 (2009).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Thompson PA, Lee MA, Ranjan R. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology14, S27–S33 (1996).
   PubMed Web of Science ®Google Scholar
• Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the ‘right stuff?’ Schizophr. Bull.26, 119–136 (2000).
   PubMed Web of Science ®Google Scholar
• McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr. Res.45, 175–184 (2000).
   PubMed Web of Science ®Google Scholar
• Leeson VC, Barnes TRE, Hutton SB, Ron MA, Joyce EM. IQ as a predictor of functional outcome in schizophrenia: a longitudinal, four-year study of first-episode psychosis. Schizophr. Res.107, 55–60 (2009).
   PubMed Web of Science ®Google Scholar
• Gold JM, Hahn B, Strauss GP, Waltz JA. Turning it upside down: areas of preserved cognitive function in schizophrenia. Neuropsychol. Rev.19, 294–311 (2009).
   PubMed Web of Science ®Google Scholar
• Malla A, Payne J. First-episode psychosis: psychopathology, quality of life, and functional outcome. Schizophr. Bull.31, 650–671 (2005).
   PubMed Web of Science ®Google Scholar
• Brewer WJ, Wood SJ, Phillips LJ et al. Generalized and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis. Schizophr. Bull.32, 538–555 (2006).
   PubMed Web of Science ®Google Scholar
• Murray RM, Lewis SW. Is schizophrenia a neurodevelopmental disorder? Br. Med. J.295, 681–682 (1987).
   PubMed Web of Science ®Google Scholar
• Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M. Behavioural and intellectual markers for schizophrenia in apparently healthy male adolescents. Am. J. Psychiatry156, 1328–1335 (1999).
   PubMed Web of Science ®Google Scholar
• Munro JC, Russell AJ, Murray RM, Kerwin RW, Jones PB. IQ in childhood psychiatric attendees predicts outcome of later schizophrenia at 21 year follow-up. Acta Psychiatr. Scand.106, 139–142 (2002).
   PubMed Web of Science ®Google Scholar
• Schenkel LS, Silverstein SM. Dimensions of premorbid functioning in schizophrenia: a review of neuromotor, cognitive, social, and behavioral domains. Genet. Soc. Gen. Psychol. Monogr.130, 241–270 (2004).
   PubMed Web of Science ®Google Scholar
• Walker E. Developmentally moderated expressions of the neuropathology of schizophrenia. Schizophr. Bull.20, 453–480 (1994).
   PubMed Web of Science ®Google Scholar
• Walker E, Lewis N, Loewy R, Palyo S. Motor dysfunction and risk for schizophrenia. Dev. Psychopathol.11, 509–524 (1999).
   PubMed Web of Science ®Google Scholar
• Zipursky R, Christensen B, Mikulis D. Stable deficits in gray matter volumes following a first episode of schizophrenia. Schizophr. Res.71, 515–516 (2004).
   Google Scholar
• Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode outcome patients: a systematic review. Arch. Gen. Psychiatry62, 975–983 (2005).
   PubMed Web of Science ®Google Scholar
• Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am. J. Psychiatry162, 1785–1804 (2005).
   PubMed Web of Science ®Google Scholar
• Barnes TRE, Leeson VC, Mutsatsa SH, Watt HC, Hutton SB, Joyce EM. Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br. J. Psychiatry193, 203–209 (2008).
   PubMed Web of Science ®Google Scholar
• Addington J, Van Mastrigt S, Addington D. Duration of untreated psychosis: impact on 2-year outcome. Psychol. Med.34, 277–284 (2004).
   PubMed Web of Science ®Google Scholar
• Harrington SM, McGorry PD, Krstev H. Does treatment delay in first-episode psychosis really matter? Psychol. Med.33, 97–110 (2003)
   Google Scholar
• Shenton M, Dickey C, Frumin M, McCarley R. A review of MRI findings in schizophrenia. Schizophr. Res.49, 1–52 (2001).
   PubMed Web of Science ®Google Scholar
• Vita A, De Peri L, Silenzi C, Dieci M. Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophr. Res.82, 75–88 (2006).
   PubMed Web of Science ®Google Scholar
• Wright I, Rabe-Hesketh S, Woodruff P, David A, Murray R, Bullmore E. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry157, 16–25 (2000).
   PubMed Web of Science ®Google Scholar
• Lappin J, Morgan K, Morgan C et al. Gray matter abnormalities associated with duration of untreated psychosis. Schizophr. Res.83, 145–153 (2006).
   PubMed Web of Science ®Google Scholar
• Pantelis C, Velakoulis D, McGorry PD et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet361, 281–288 (2003).
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Malaspina D, Jarskog LF. Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. Prim. Psychiatry13, 1–15 (2006).
   Google Scholar
• McGlashan TH, Miller TJ, Woods SW. Pre-onset detection and intervention research in schizophrenia psychoses: current estimates of benefit and risk. Schizophr. Bull.27, 563–570 (2001).
   PubMed Web of Science ®Google Scholar
• Phillips LJ, McGorry P, Yung AR, McGlashan TH, Cornblatt B, Klosterkotter J. Prepsychotic phase of schizophrenia and related disorders: recent progress and future opportunities. Br. J. Psychiatry187, 33–44 (2005).
   Google Scholar
• Cornblatt BA, Lencz T, Smith CW, Cornell CU, Auther AM, Nakayama E. The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr. Bull.29, 633–651 (2003).
   PubMed Web of Science ®Google Scholar
• Schultze-Lutter F, Ruhrmann S, Berning J, Maier W, Klosterkotter J. Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr. Bull.36, 182–191 (2010).
   PubMed Web of Science ®Google Scholar
• an der Heiden W, Hafner H. The epidemiology of onset and course of schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci.250, 292–303 (2000).
   PubMed Web of Science ®Google Scholar
• Rosen JL, Miller TJ, D’Andrea JT, McGlashan TH, Woods SW. Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr. Res.85, 124–131 (2006).
   PubMed Web of Science ®Google Scholar
• Gross G, Huber G, Klosterkotter J, Linz M. [BSABS: Bonn Scale for the Assessment of Basic Symptoms]. Springer, Berlin, Germany (1987).
   Google Scholar
• Yung AR, McGorry PD. The initial prodrome in psychosis: descriptive and qualitative aspects. Aust. NZ J. Psychiatry30, 587–599 (1996).
   PubMed Web of Science ®Google Scholar
• Schultze-Lutter F, Klosterkotter J. Bonn Scale for the Assessment of Basic Symptoms – prediction list, BSABS-P. University of Cologne, Cologne, Germany (2002).
   Google Scholar
• Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch. Gen. Psychiatry58, 158–164 (2001).
   PubMed Web of Science ®Google Scholar
• Siever LJ, Davis KL. The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am. J. Psychiatry161, 398–413 (2004).
   PubMed Web of Science ®Google Scholar
• Olsen KA, Rosenbaum B. Prospective investigations of the prodromal state of schizophrenia: review of studies. Acta Psychiatr. Scand.113, 247–272 (2006).
   PubMed Web of Science ®Google Scholar
• Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell’Olio M. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust. NZ J. Psychiatry39, 964–971 (2005).
   PubMed Web of Science ®Google Scholar
• Yung AR, McGorry PD. The prodromal phase of first episode psychosis: past and current conceptualizations. Schizophr. Bull.22, 353–370 (1996).
   PubMed Web of Science ®Google Scholar
• McGorry PD, Yung AR, Phillips LJ. Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophr. Res.51, 17–29 (2001).
   PubMed Web of Science ®Google Scholar
• de Koning MB, Bloemen OJN, van Amelsvoort TAMJ et al. Early intervention in patients at ultra high risk of psychosis: benefits and risks. Acta Psychiatr. Scand.119, 426–442 (2009).
   PubMed Web of Science ®Google Scholar
• Cadenhead K. Vulnerability markers in the schizophrenia spectrum: implications for phenomenology, genetics, and the identification of the schizophrenia prodrome. Psychiatry Clin. N. Am.25, 837–853 (2002).
   PubMedGoogle Scholar
• Mason O, Startup M, Halpin S, Schall U, Conrad A, Carr V. Risk factors for transition to first episode psychosis among individuals with “at-risk mental states”. Schizophr. Res.71, 227–237 (2004).
   PubMed Web of Science ®Google Scholar
• McGlashan TH, Zipursky RB, Perkins DO et al. The PRIME North American randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr. Res.61, 7–18 (2003).
   PubMed Web of Science ®Google Scholar
• Miller TJ, McGlashan TH, Rosen JL, Cadenhead DO, Ventura J, McFarlane CA. Prodromal assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr. Bull.29, 703–715 (2003).
   PubMed Web of Science ®Google Scholar
• Morrison AP, French P, Walford L et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk. Br. J. Psychiatry185, 291–297 (2004).
   PubMed Web of Science ®Google Scholar
• Nieman DH, Rike WH, Becker HE et al. Prescription of antipsychotic medication to patients at ultra high risk of developing psychosis. Int. Clin. Psychopharmacol.24, 223–228 (2009).
   Google Scholar
• Cannon TD, Cadenhead K, Cornblatt B et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry65, 28–37 (2008).
   PubMed Web of Science ®Google Scholar
• Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr. Res.67, 131–142 (2004).
   PubMed Web of Science ®Google Scholar
• Bak M, Delespaul P, Hanssen M, de Graaf R, Vollebergh W, van Os J. How false are “false” positive psychotic symptoms? Schizophr. Res.62, 187–189 (2003).
   Google Scholar
• Yung AR, Yuen HP, Berger G et al. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr. Bull.33, 673–681 (2007).
   PubMed Web of Science ®Google Scholar
• Green MF. What are the functional consequences of the neurocognitive deficits in schizophrenia? Am. J. Psychiatry153, 321–330 (1996).
   PubMed Web of Science ®Google Scholar
• Harvey PD, Howanitz E, Parrella M et al. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am. J. Psychiatry155, 1080–1086 (1998).
   PubMed Web of Science ®Google Scholar
• Harvey PD, Silverman JM, Mohs RC et al. Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol. Psychiatry45, 32–40 (1999).
   PubMed Web of Science ®Google Scholar
• Jahshan C, Heaton RK, Golshan S, Cadenhead KS. Course of neurocognitive deficits in the prodrome and first episode of schizophrenia. Neuropsychology24, 109–120 (2010).
   PubMed Web of Science ®Google Scholar
• Bersani G, Orlandi V, Kotzalidis GD, Pancheri P. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur. Arch. Psychiatry Clin. Neurosci.252, 86–92 (2002).
   PubMed Web of Science ®Google Scholar
• Boydell J, Dean K, Dutta R, Giouroukou E, Fearon P, Murray R. A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: implications for the concept of cannabis psychosis. Schizophr. Res.93, 203–210 (2007).
   PubMed Web of Science ®Google Scholar
• Hambrecht M, Hafner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust. NZ J. Psychiatry34, 468–475 (2000).
   PubMed Web of Science ®Google Scholar
• Cassano GB, Pini S, Saettoni M, Rucci, P, Dell’Osso L. Occurrence and clinical correlates of psychiatric comorbididty in patients with psychotic disorders. J. Clin. Psychiatry59, 60–68 (1998).
   PubMed Web of Science ®Google Scholar
• Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, Van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction99, 1333–1341 (2004).
   PubMed Web of Science ®Google Scholar
• Compton MT, Weiss PS, West JC, Kaslow NJ. The associations between substance use disorders, schizophrenia-spectrum disorders, and Axis IV psychosocial problems. Soc. Psychiatry Psychiatr. Epidemiol.40, 939–946 (2005).
   PubMed Web of Science ®Google Scholar
• Drake RE, Wallach MA. Substance abuse among the chronic mentally ill. Hosp. Community Psychiatry40, 1041–1046 (1989).
   PubMedGoogle Scholar
• D’Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G. d-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry57, 594–608 (2005).
   PubMed Web of Science ®Google Scholar
• Kavanagh DJ. Management of co-occuring substance use disorders. In: Clinical Handbook of Schizophrenia. Mueser KT, Jeste DV (Eds.). Guilford Press, NY, USA, 459–470 (2008).
   Google Scholar
• Compton MT, Goulding SM, Walker EF. Cannabis use, first-episode psychosis, and schizotypy: a summary and synthesis of recent literature. Curr. Psychiatry Rev.3, 161–171 (2007).
   Google Scholar
• Arseneault LM, Cannon M, Witton J, Murray M. Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiatry184, 110–117 (2004).
   PubMed Web of Science ®Google Scholar
• Phillips LJ, Curry C, Yung AR, Yuen HP, Adlard S, McGorry PD. Cannabis use is not associated with development of psychosis in an ‘ultra’ high-risk group. Aust. NZ J. Psychiatry36, 800–806 (2002).
   PubMed Web of Science ®Google Scholar
• Kristensen K, Cadenhead KS. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res.151, 151–154 (2007).
   PubMed Web of Science ®Google Scholar
• Cannon T. Neurodevelopment and the transition from schizophrenia prodrome to schizophrenia: research imperatives. Biol. Psychiatry64, 737–738 (2008).
   Google Scholar
• McGorry PD, Nelson B, Amminger P et al. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J. Clin. Psychiatry70, 1206–1212 (2009).
   PubMed Web of Science ®Google Scholar
• Goetz D, Goetz R, Yale S et al. Comparing early and chronic psychosis clinical characteristics. Schizophr. Res.70, 120 (2004).
   Google Scholar
• Lieberman JA, Tollefson GD, Charles C et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry62, 361–370 (2005).
   PubMed Web of Science ®Google Scholar
• Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull.25, 201–222 (1999).
   PubMed Web of Science ®Google Scholar
• Keefe RSE, Sweeney JA, Hongbin G, Hamer RM, Perkins DO, McEvoy JP. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry164, 1061–1071 (2007).
   PubMed Web of Science ®Google Scholar
• Tandon R, DeQuardo J, Taylor S et al. Phasic and enduring negative symptoms in schizophrenia: Biological markers and relationship to outcome. Schizophr. Res.45, 191–201 (2000).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Thompson PA, Lee MA, Ranjan R. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology14, S27–S33 (1996).
   PubMed Web of Science ®Google Scholar
• McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr. Res.45, 175–184, (2000).
   PubMed Web of Science ®Google Scholar
• McGorry PD, Yung AR, Phillips LJ et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry59, 921–928 (2002).
   PubMed Web of Science ®Google Scholar
• Phillips LJ, McGorry PD, Yuen JP et al. Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr. Res.96, 25–33 (2007).
   PubMed Web of Science ®Google Scholar
• Cannon TD, van Erp TG, Rosso IM et al. Fetal hypoxia and structural brain abnormalities in schizophrenic patients, their siblings, and controls. Arch. Gen. Psychiatry59, 35–41 (2002).
   PubMed Web of Science ®Google Scholar
• Woods SW, Breier A, Zipursky RB et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol. Psychiatry54, 453–564 (2003).
   PubMed Web of Science ®Google Scholar
• McGlashan TH, Zipursky RB, Perkins DO. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry163, 790–799 (2006).
   PubMed Web of Science ®Google Scholar
• Woods SW, Tully EM, Walsh BC, Hawkins KA, Callahan JL, Cohen SJ. Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br. J. Psychiatry191, S96-S101 (2007).
   Web of Science ®Google Scholar
• Ruhrmann S, Bechdolf A, Kuhn K-U, Wagner M, Schultze-Lutter F, Janssen B. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br. J. Psychiatry191, S88–S95 (2007).
   Web of Science ®Google Scholar
• Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr. Scand.114, 3–13 (2006).
   PubMed Web of Science ®Google Scholar
• Cornblatt BA, Lencz T, Smith CW et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J. Clin. Psychiatry68, 546–557 (2007).
   PubMed Web of Science ®Google Scholar
• Fusor-Poli P, Valmaggia L, McGuire P. Can antidepressants prevent psychosis? Lancet370, 1746–1748 (2007).
   Google Scholar
• Walker EF, Cornblatt BA, Addington J et al. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal sample. Schizophr. Res.115, 50–57 (2009).
   PubMed Web of Science ®Google Scholar
• Benton MK, Schroeder HE. Social skills training with schizophrenics: a meta-analytic evaluation. J. Consult. Clin. Psychol.58, 741–747 (1990).
   PubMed Web of Science ®Google Scholar
• Combs DR, Adams SD, Penn DL, Roberts D, Tiegreen J, Stern P. Social cognition and interaction traning (SCIT) for inpatients with schizophrenia spectrum disorders: preliminary findings. Schizophr. Res.91, 112–116 (2007).
   PubMed Web of Science ®Google Scholar
• Pitschel-Walz G, Leucht S, Bauml J, Kissling W, Engel RR. The effect of family interventions on relapse and rehospitalization in schizophrenia – a meta-analysis. Schizophr. Bull.27, 73–92 (2001).
   PubMed Web of Science ®Google Scholar
• McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. Am. J. Psychiatry164, 1791–1802 (2007).
   PubMed Web of Science ®Google Scholar
• Gould RA, Mueser KT, Bolton E, Mays V, Goff D. Cognitive therapy for psychosis in schizophrenia: an effect size analysis. Schizophr. Res.48, 3335–3342 (2001).
   Google Scholar
• Gaudiano BA. Is symptomatic improvement in clinical trials of cognitive–behavioral therapy for psychosis clinically significant? J. Psychiatr. Pract.12, 11–23 (2006).
   Google Scholar
• Pilling S, Bebbington P, Kuipers E et al. Psychological treatments in schizophrenia: II. Meta-analyses of randomized controlled trials of social skills training and cognitive remediation. Psychol. Med.32, 783–791 (2002).
   PubMed Web of Science ®Google Scholar
• Rathod S, Turkington D. Cognitive–behavioral therapy for schizophrenia: a review. Curr. Opin. Psychiatry18, 159–163, (2005).
   PubMed Web of Science ®Google Scholar
• Turkington D, Dudley R, Warman DM, Beck AT. Cognitive–behavioral therapy for schizophrenia: a review. J. Psychiatr. Pract.10, 5–16 (2004).
   PubMedGoogle Scholar
• Zimmerman G, Favrod J, Trieu VH, Pomini V. The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis. Schizophr. Res.77, 1–9 (2005).
   PubMed Web of Science ®Google Scholar
• Falloon IR. Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry55, 4–15 (1992).
   PubMed Web of Science ®Google Scholar
• Morrison AP, French P, Parker S et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr. Bull.33, 682–687 (2007).
   PubMed Web of Science ®Google Scholar
• Bechdolf A, Wagner M, Veith V et al. Randomized controlled multicentre trial of cognitive behavior therapy in the early intitial prodromal state: effects on social adjustment post treatment. Early Intervent. Psychiatry1, 71–78 (2007).
   PubMed Web of Science ®Google Scholar
• Nordentoft M, Thorup A, Petersen L et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trail. A randomized clinical trial of integrated treatment and standard treatment. Schizophr. Res.83, 29–40 (2006).
   PubMedGoogle Scholar
• Berger GE, Smesny S, Amminger GP. Bioactive lipids in schizophrenia. Int. Rev. Psychiatry18, 85–98 (2006).
   PubMed Web of Science ®Google Scholar
• Amminger GP, Berger GE, Schzfer MR, Klier C, Friedrich MH, Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol. Psychiatry61, 551–553 (2007).
   PubMed Web of Science ®Google Scholar
• Berger GE, Proffitt T-M, McConchie M, Yuen JP, Wood SJ, Amminger P. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J. Clin. Psychiatry68, 1867–1875 (2007).
   PubMed Web of Science ®Google Scholar
• Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry159, 1596–1598 (2002).
   PubMed Web of Science ®Google Scholar
• Richardson AJ, Montgomery P. The Oxford–Durham study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics115, 1360–1366 (2005).
   PubMed Web of Science ®Google Scholar
• Amminger GP, Schaefer MR, Papageorgiou K et al. Omega 3 fatty acids reduce the risk of early transition to psychosis in ultra-high risk individuals: a double-blind randomized, placebo-controlled treatment study. Schizophr. Bull.33(Suppl.), 418–419. (2007).
   Web of Science ®Google Scholar
• Amminger GP, Schaefer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM. Long-chain omega-3 fatty acids for indicated prevention of psychiatric disorders. Arch. Gen. Psychiatry67, 146–154 (2010).
   PubMed Web of Science ®Google Scholar
• Cornblatt BA, Lencz T, Kane JM. Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr. Res.5131–38 (2001).
   Google Scholar
• McGorry PD, Yung A, Phillips L. Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophr. Res.51, 17–29 (2001).
   PubMed Web of Science ®Google Scholar
• McGlashan T. Psychosis treatment prior to psychosis onset: ethical issues. Schizophr. Res.51, 47–54 (2001).
   PubMed Web of Science ®Google Scholar
• Haroun N, Dunn L, Haroun A, Cadenhead KS. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr. Bull.32, 166–178 (2006).
   PubMed Web of Science ®Google Scholar
• McGlashan TH. Early detection and intervention in psychosis: an ethical paradigm shift. Br. J. Psychiatry187, S113–S115 (2005).
   Web of Science ®Google Scholar
• Compton MR, Goulding SM, Ramsay CE, Addington J, Corcoran C, Walker EF. Early detection and intervention for psychosis: perspectives from North America. Clin. Neuropsychiatry5, 263–272 (2008).
   Google Scholar